Rein Therapeutics, Inc. (RNTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on October 24, 2025, covering events occurring on October 23, 2025. Rein Therapeutics, Inc., a Delaware corporation, reported the execution of a third Pre-Paid Advance under an existing agreement with YA II PN, Ltd. ("Yorkville").
Key Financial Metrics and Transaction Details
The filing details a Pre-Paid Advance Agreement (PPA) allowing the Company to request advances up to $6.0 million over 12 months. Key terms and recent activity include:
- Advance Terms: Advances are purchased at 95% of face value. Interest accrues at 8% annually, increasing to 18% upon default. Advances are due 12 months after issuance.
- Repayment Mechanism: Yorkville may require the issuance of common stock to offset outstanding principal and accrued interest.
- Third Advance (Oct 23, 2025): Face amount of $1.0 million; net proceeds of $0.95 million.
- Second Advance (Sept 8, 2025): Face amount of $1.0 million; net proceeds of $0.95 million. Partially repaid via issuance of 927,107 shares at an average price of $1.0825, offsetting $1,003,573 of principal and interest.
- First Advance (July 29, 2025): Face amount of $1.0 million; net proceeds of $0.95 million. Partially repaid via issuance of 953,765 shares at an average price of $1.0562, offsetting $1,007,342 of principal and interest.
The filing does not provide comprehensive revenue, profit, cash flow, or total debt figures for the reporting period.
Material Changes
The primary material change is the increase in outstanding debt obligations and the dilution of existing shareholders due to the issuance of unregistered equity securities to satisfy the PPA terms. The Company has now drawn $3.0 million in face value advances under the agreement, with $1.0 million drawn on the date of this report.
Outlook, Risks, and Contingencies
- Equity Dilution: The agreement allows Yorkville to force the issuance of common stock to repay advances, creating potential dilution risk.
- Interest Rate Risk: The interest rate on outstanding balances can increase from 8% to 18% in the event of default.
- Liquidity: The transaction provides immediate liquidity ($0.95 million net proceeds) but creates a direct financial obligation due within 12 months.
- Unregistered Sales: The securities were sold in a private placement under Section 4(a)(2) of the Securities Act of 1933 without an underwriter.
Investor Verification Checklist
- Verify the total outstanding principal and accrued interest under the PPA as of the filing date.
- Confirm the total number of shares issued to Yorkville to date and the resulting dilution impact on existing shareholders.
- Review the full text of the Pre-Paid Advance Agreement (Exhibit 10.1) for specific default triggers and limitations on future advances.
- Assess the Company's current cash position relative to the upcoming 12-month maturity of the advances.